Geoffroy Pineau-Valencienne

Geoffroy Pineau-Valencienne has extensive experience in venture capital, private equity, M&A, and capital markets transactions. He represents a large number of private and public companies at every stage of development, from entrepreneurial start-ups to global corporations, particularly in the life sciences and technology fields, as well as financial and industrial investors.

Geoffroy's recent experience includes representation of technology and life sciences companies such as Amoéba, Amolyt Pharma, BonitaSoft, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Talend, and Trace One. His recent investor-side representations include: AbbVie, Alven, Andera, Balderton, BioMed, Bpifrance, Breega, CTI Life Sciences, Elaia, Havenrock, HI Inov, Idinvest, Kurma, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Sofinnova Partners, Supernova, Ventech, Wellington, and Western Digital.

Illustrative examples of the transactions in which Geoffroy acted as lead lawyer include venture capital financings, either on issuer- or investor-side (in connection with the financing rounds of Alice & Bob, Amolyt Pharma, Alédia, CorWave, Domain Therapeutics, Inotrem, Masteos, MadBox, May Health, Mutabilis, Lendix, UpMem, UroMems, TriCares, and Vulkam), private and public M&A transactions ($1.05 billion acquisition of Amolyt Pharma by AstraZeneca, acquisition of Pipplet by ETS Global; sales of Alizé Pharma to Millendo, Mathym to Baikowski, Endocontrol to Canady Life Sciences, and SoCloz to Savoye; and the reverse merger of Genticel to Genkyotex), and IPOs and follow-on offerings (Amoéba, Genticel, and Enertime on the main or Growth market of Euronext Paris and Cellectis and Talend on Nasdaq).